Cidara/CDTX

$0.75

2.74%
-
1D1W1MYTD1YMAX

About Cidara

Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for patients facing serious diseases. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. The Company’s primary focus is using its Cloudbreak platform to develop a potential new class of drugs called drug-Fc conjugates (DFCs), for the prevention and treatment of serious diseases. This technology couples’ potent inhibitors to a human antibody fragment to create long-acting DFCs designed to inhibit multiple disease targets. Its advanced DFC program is CD388, a long-acting antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials.

Ticker

CDTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jeffrey Stein

Employees

73

Headquarters

San diego, United States

Cidara Metrics

BasicAdvanced
$74.73M
Market cap
-
P/E ratio
-$0.39
EPS
1.03
Beta
-
Dividend rate
$74.73M
1.02963
$1.48
$0.59
687.81K
1.62
1.551
-47.11%
-366.84%
-99.57%
1.322
9.277
9.298
-7.75%
26.97%
45.4%

What the Analysts think about Cidara

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 5 analysts.
646.67% upside
High $7.00
Low $3.00
$0.75
Current price
$5.60
Average price target

Cidara Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-63.77% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$12.7M
67.11%
Net income
$-8.1M
-34.15%
Profit margin
-63.77%
-60.6%

Cidara Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 44.62%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.19
$0.03
-$0.14
-$0.09
-
Expected
-$0.17
-$0.04
-$0.13
-$0.16
-$0.10
Surprise
13.43%
-181.82%
7.69%
-44.62%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Cidara stock?

Cidara (CDTX) has a market cap of $74.73M as of April 17, 2024.

What is the P/E ratio for Cidara stock?

The price to earnings (P/E) ratio for Cidara (CDTX) stock is 0 as of April 17, 2024.

Does Cidara stock pay dividends?

No, Cidara (CDTX) stock does not pay dividends to its shareholders as of April 17, 2024.

When is the next Cidara dividend payment date?

Cidara (CDTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Cidara?

Cidara (CDTX) has a beta rating of 1.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Cidara stock price target?

The target price for Cidara (CDTX) stock is $5.6, which is 646.67% above the current price of $0.75. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Cidara stock

Buy or sell Cidara stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing